First Experience with Osimertinib in Patients with Newly Developed T790M Mutation Previously Treated with EGFR - TKIs in Croatia

被引：0
|
作者：
Jakopovic, M. [1 ]
Bitar, L. [1 ]
Seiwerth, F. [1 ]
Plestina, S. [1 ]
Kukulj, S.
Seiwerth, S. [2 ,3 ]
Misic, M. [3 ]
Redzepi, G. [1 ]
Samarzija, M. [2 ]
机构：
[1] Univ Hosp Ctr Zagreb, Dept Resp Dis Jordanovac, Zagreb, Croatia
[2] Univ Hosp Ctr Zagreb, Zagreb, Croatia
[3] Univ Hosp Ctr Zagreb, Clin Dept Pathol, Zagreb, Croatia
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
D O I：
10.1016/j.jtho.2017.09.1500
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.01-059
引用
收藏
页码：S2224 / S2224
页数：1
相关论文
共 50 条
  • [31] Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation
    Joshi, Asim
    Butle, Ashwin
    Hait, Supriya
    Mishra, Rohit
    Trivedi, Vaishakhi
    Thorat, Rahul
    Choughule, Anuradha
    Noronha, Vanita
    Prabhash, Kumar
    Dutt, Amit
    TRANSLATIONAL ONCOLOGY, 2022, 22
  • [32] Intracranial Activity of Osimertinib in Naive EGFRm T790M(-) And Treated EGFRm T790M(+) NSCLC Patients with Asymptomatic Brain Metastases
    Peled, N.
    Nechushtan, H.
    Ilouze, M.
    Dudnik, E.
    Inbar, E.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2223 - S2223
  • [33] Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation
    Miyashita, Yosuke
    Ko, Ryo
    Shimada, Naoko
    Mitsuishi, Yoichiro
    Miura, Keita
    Matsumoto, Naohisa
    Asao, Tetsuhiko
    Shukuya, Takehito
    Shibayama, Rina
    Koyama, Ryo
    Takahashi, Kazuhisa
    THORACIC CANCER, 2021, 12 (03) : 329 - 338
  • [34] Clinical Characteristics of T790M in Pre and Post Treatment with EGFR TKIs
    Ke, Ee
    Zhang, Qiuyi
    Zhou, Qing
    Wu, Yilong
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S778 - S778
  • [35] Clinical characteristics of T790M in pre and post treatment with EGFR TKIs
    Ke, E.
    Zhang, Q.
    Zhou, Q.
    Wu, Y. -L.
    ANNALS OF ONCOLOGY, 2015, 26 : 143 - 143
  • [36] Tissue Is the Issue for Diagnosis of EGFR T790M Mutation
    Khan, Jenna
    Pritchard, Colin C.
    Martins, Renato G.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (07) : E91 - E92
  • [37] Association between EGFR T790M status and progression patterns during initial EGFR-TKIs treatment in patients harboring EGFR mutation
    Oya, Y.
    Yoshida, T.
    Tanaka, K.
    Kuroda, H.
    Shimizu, J.
    Horio, Y.
    Sakao, Y.
    Inaba, Y.
    Hida, T.
    Yatabe, Y.
    ANNALS OF ONCOLOGY, 2016, 27
  • [38] An audit on the use of osimertinib in T790M EGFR+ patients at West Suffolk Hospital
    Davis, O.
    Patterson, D.
    Martin, A.
    LUNG CANCER, 2019, 127 : S40 - S40
  • [39] Osimertinib Benefit in ctDNA T790M Positive, EGFR-Mutant NSCLC Patients
    Remon, Jordi
    Caramella, Caroline
    Joelet, Cecile
    Lacroix, Ludovic
    Lawson, Andrew
    Smalley, Sarah
    Howarth, Karen
    Gale, Davina
    Rosenfeld, Nitzan
    Green, Emma
    Plagnol, Vincent
    Planchard, David
    Bluthgen, Maria
    Gazzah, Annas
    Pannet, Chloe
    Nicotra, Claudio
    Soria, Jean-Charles
    Besse, Benjamin
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1254 - S1255
  • [40] ASTRIS real world study of osimertinib in patients (pts) with EGFR T790M NSCLC: Efficacy analysis by tissue or plasma T790M test
    Freitas, H. C.
    Park, K.
    Kim, D-W.
    Tiseo, M.
    Hochmair, M. J.
    Chang, G-C.
    Shi, Y-K.
    Moran, T.
    Chen, Y.
    Laskin, J.
    Solomon, B.
    Miranda, M.
    Rigas, J.
    Cheema, P. K.
    Kim, S-W.
    ANNALS OF ONCOLOGY, 2018, 29 : 149 - 149
12345